SG11201505818WA - Treatment of multiple sclerosis with laquinimod - Google Patents
Treatment of multiple sclerosis with laquinimodInfo
- Publication number
- SG11201505818WA SG11201505818WA SG11201505818WA SG11201505818WA SG11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA
- Authority
- SG
- Singapore
- Prior art keywords
- laquinimod
- treatment
- multiple sclerosis
- sclerosis
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361765394P | 2013-02-15 | 2013-02-15 | |
| US201361911106P | 2013-12-03 | 2013-12-03 | |
| PCT/US2014/016278 WO2014127139A1 (en) | 2013-02-15 | 2014-02-13 | Treatment of multiple sclerosis with laquinimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201505818WA true SG11201505818WA (en) | 2015-08-28 |
Family
ID=51351655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505818WA SG11201505818WA (en) | 2013-02-15 | 2014-02-13 | Treatment of multiple sclerosis with laquinimod |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140235670A1 (https=) |
| EP (1) | EP2956137A4 (https=) |
| JP (1) | JP2016510343A (https=) |
| KR (1) | KR20150119227A (https=) |
| CN (1) | CN105163737A (https=) |
| AU (1) | AU2014216199A1 (https=) |
| BR (1) | BR112015019564A2 (https=) |
| CA (1) | CA2900503A1 (https=) |
| CL (1) | CL2015002181A1 (https=) |
| EA (1) | EA201591507A1 (https=) |
| HK (2) | HK1218254A1 (https=) |
| IL (1) | IL240014A0 (https=) |
| MX (1) | MX2015010296A (https=) |
| PE (1) | PE20151526A1 (https=) |
| SG (1) | SG11201505818WA (https=) |
| TW (1) | TW201442709A (https=) |
| UY (1) | UY35328A (https=) |
| WO (1) | WO2014127139A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| WO2015168103A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| CN114699409A (zh) * | 2014-10-16 | 2022-07-05 | 诺华股份有限公司 | 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合 |
| US10091217B2 (en) | 2016-06-21 | 2018-10-02 | Logrhythm, Inc. | Risk based priority processing of data |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN110382052A (zh) * | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| US20230296628A1 (en) * | 2020-07-09 | 2023-09-21 | Oklahoma Medical Research Foundation | Biomarkers for Identifying Relapses in Multiple Sclerosis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| KR20150065951A (ko) * | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| US8138201B2 (en) * | 2007-07-11 | 2012-03-20 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| US20110268699A1 (en) * | 2008-12-11 | 2011-11-03 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
| JP2012530701A (ja) * | 2009-06-19 | 2012-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症のラキニモドでの治療 |
| AU2011338647A1 (en) * | 2010-12-07 | 2013-07-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| AU2012286701A1 (en) * | 2011-07-28 | 2014-03-06 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| BR112015007782A2 (pt) * | 2012-10-12 | 2017-07-04 | Teva Pharma | laquinimod para reduzir danos talâmicos na esclerose múltipla |
| WO2015168103A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
-
2014
- 2014-02-13 BR BR112015019564A patent/BR112015019564A2/pt active Search and Examination
- 2014-02-13 HK HK16106269.3A patent/HK1218254A1/zh unknown
- 2014-02-13 KR KR1020157024953A patent/KR20150119227A/ko not_active Withdrawn
- 2014-02-13 WO PCT/US2014/016278 patent/WO2014127139A1/en not_active Ceased
- 2014-02-13 HK HK16106220.1A patent/HK1218251A1/zh unknown
- 2014-02-13 CA CA2900503A patent/CA2900503A1/en not_active Abandoned
- 2014-02-13 SG SG11201505818WA patent/SG11201505818WA/en unknown
- 2014-02-13 US US14/180,173 patent/US20140235670A1/en not_active Abandoned
- 2014-02-13 MX MX2015010296A patent/MX2015010296A/es unknown
- 2014-02-13 AU AU2014216199A patent/AU2014216199A1/en not_active Abandoned
- 2014-02-13 CN CN201480009035.XA patent/CN105163737A/zh active Pending
- 2014-02-13 EP EP14751103.4A patent/EP2956137A4/en not_active Withdrawn
- 2014-02-13 JP JP2015558130A patent/JP2016510343A/ja active Pending
- 2014-02-13 PE PE2015001745A patent/PE20151526A1/es not_active Application Discontinuation
- 2014-02-13 EA EA201591507A patent/EA201591507A1/ru unknown
- 2014-02-14 TW TW103104987A patent/TW201442709A/zh unknown
- 2014-02-14 UY UY0001035328A patent/UY35328A/es not_active Application Discontinuation
-
2015
- 2015-07-19 IL IL240014A patent/IL240014A0/en unknown
- 2015-08-05 CL CL2015002181A patent/CL2015002181A1/es unknown
-
2017
- 2017-11-13 US US15/811,139 patent/US20180064702A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| UY35328A (es) | 2014-09-30 |
| CN105163737A (zh) | 2015-12-16 |
| EA201591507A1 (ru) | 2015-12-30 |
| HK1218251A1 (zh) | 2017-02-10 |
| EP2956137A1 (en) | 2015-12-23 |
| CA2900503A1 (en) | 2014-08-21 |
| WO2014127139A1 (en) | 2014-08-21 |
| BR112015019564A2 (pt) | 2017-07-18 |
| US20140235670A1 (en) | 2014-08-21 |
| CL2015002181A1 (es) | 2016-06-03 |
| HK1218254A1 (zh) | 2017-02-10 |
| TW201442709A (zh) | 2014-11-16 |
| IL240014A0 (en) | 2015-09-24 |
| KR20150119227A (ko) | 2015-10-23 |
| MX2015010296A (es) | 2016-05-05 |
| PE20151526A1 (es) | 2015-11-20 |
| AU2014216199A1 (en) | 2015-09-03 |
| US20180064702A1 (en) | 2018-03-08 |
| EP2956137A4 (en) | 2016-08-03 |
| JP2016510343A (ja) | 2016-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287516A (en) | Medicinal uses of empagliflozin | |
| IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| IL245408B (en) | Converted benzamides for the treatment of arthropods | |
| IL241101B (en) | Medicinal uses of empagliflozin | |
| SG11201507121RA (en) | Treatment of cataplexy | |
| IL241102B (en) | Medicinal uses of empagliflozin | |
| SI2981271T1 (sl) | Terapevtske uporabe empagliflozina | |
| IL240014A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| IL245373A0 (en) | Treatment of glaucoma by laquinimod | |
| IL241096B (en) | Treatment methods | |
| IL243486A0 (en) | Treatment of multiple sclerosis using a combination of laquinimod and flupirtine | |
| IL244620A0 (en) | A drug combination including laquinimod for the treatment of multiple sclerosis | |
| ZA201601626B (en) | Treatment of gases | |
| GB2525530B (en) | Treatment of hard surfaces | |
| IL246078A0 (en) | Treatment of multiple sclerosis by a combination of laquinimod and triflunomide | |
| HK1225291A1 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| GB201322778D0 (en) | Method of treatment | |
| GB201314882D0 (en) | Method of treatment | |
| GB201306411D0 (en) | Treatment of inflammatory conditions | |
| AU2013901359A0 (en) | Methods of Treatment |